Perfluorocarbon-based nanomedicine: emerging strategy for diagnosis and treatment of diseases

Nanotechnology has been considered as a promising strategy for diagnosis and treatment of various diseases. However, the stability and circulation times of the conventional nano-carriers, such as liposomes and micelles, are still unsatisfied. Perfluorocarbons (PFCs) are biologic inert synthetic mate...

Full description

Saved in:
Bibliographic Details
Published in:MRS communications 2018-06, Vol.8 (2), p.303-313
Main Authors: Zhang, Tingbin, Zhang, Qian, Tian, Jian-Hua, Xing, Jin-Feng, Guo, Weisheng, Liang, Xing-Jie
Format: Article
Language:English
Subjects:
Biomaterials
Blood substitutes
Characterization and Evaluation of Materials
Diagnosis
Diseases
Drug delivery systems
Drugs
Efficiency
FDA approval
Fluorination
Fluorine
Genes
Libraries
Liposomes
Magnetic resonance imaging
Materials Engineering
Materials Science
Medical diagnosis
Medical research
Nanoemulsions
Nanotechnology
NMR
Nuclear magnetic resonance
Perfluorocarbons
Photodynamic therapy
Polymer Sciences
Prospective Article
Prospective Articles
Reagents
Stability
Trends
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanotechnology has been considered as a promising strategy for diagnosis and treatment of various diseases. However, the stability and circulation times of the conventional nano-carriers, such as liposomes and micelles, are still unsatisfied. Perfluorocarbons (PFCs) are biologic inert synthetic materials, which are highly hydrophobic and have a tendency to self-aggregation. Additionally, PFCs themselves can act as 19F magnetic resonance imaging agents and oxygen carriers. Thus, the construction of the fluorinated carriers will not only improve the stability of the carriers, but also endow them with additional functions. Here we review the recent advances of PFC-based nanosystems for diagnosis and treatment of diseases.
ISSN:2159-6859
2159-6867
DOI:10.1557/mrc.2018.49